Phylex BioSciences announces Nipah virus vaccine initiative with its nanoparticle mRNA vaccine technology

Since late August the Indian state of Kerala is experiencing its fourth outbreak of the Nipah virus in five years.  Nipah virus is a bat-borne virus discovered in 1999 that causes fever, vomiting, respiratory distress and encephalitis. The Nipah virus has a fatality rate between 40% and 75% and has triggered the closure of schools, offices and public transports in Kerala.

Over the past two decades the Nipah virus has spilled over into humans in Bangladesh, India, Malaysia, the Philippines and Singapore. Fruit bats of the genus Pteropus are a natural reservoir of the Nipah virus and are widely distributed in East Africa, South-East Asia and Australia, with an estimated 2 billion people worldwide at risk of Nipah virus outbreaks. There is no approved vaccine or treatment for the Nipah virus.

Phylex BioSciences published last year the proof-of-principle of its second-generation nanoparticle mRNA vaccine against the SARS-CoV-2 delta virus. The same technology is directly applicable to the development of a Nipah virus vaccine. The mRNA vaccine candidate encodes for a nanoparticle displaying 60 copies of the antigen based upon the head domain of the G protein of the Nipah virus. The anticipated advantages of the nanoparticle vaccine are superior immune response, long-term protection from cell-mediated immunity, and protection against dissemination of the virus in the brain.

“The Nipah virus outbreak is a reminder of the increased risk of zoonotic diseases as the world population expands and encroaches into wild habitats. We have the technology to rapidly develop next generation mRNA vaccines that will effectively fight against these new viruses”, said Pascal Brandys, co-founder and CEO of Phylex BioSciences, which is currently developing a next generation mRNA Nipah virus vaccine. “Our mRNA vaccine encoding for a highly immunogenic nanoparticle provides a flexible platform for rapid development of a new Nipah virus vaccine and will be of great value in combatting Nipah virus and other similar viruses”.

Founded at the beginning of the SARS-CoV-2 pandemic by genomics pioneer Pascal Brandys and coronavirus specialist Jens Herold, Phylex BioSciences is the first company to pursue the development of a nanoparticle mRNA vaccine against the Nipah virus.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!